Episodebeskrivelse
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended Oct. 16, 2026. This time—Tremfya rises from Stelara’s ashes; Pfizer uses mature brands as testbeds; Chinese science shines in Q3 deals; autoimmune win and setback for Argenx; and Japan looks to restore biopharma competitiveness.
Story links…

